Перспективы терапии легочной артериальной гипертензии ингаляционным илопростом
https://doi.org/10.18093/0869-0189-2012-0-1-95-102
Аннотация
Перспективы терапии легочной артериальной гипертензии ингаляционным илопростом.
Об авторе
С. Н. Авдеев
ФГУ "НИИ пульмонологии" ФМБА России
Россия
Россия
д. м. н., проф., руководитель клинического отдела
105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел. / факс: (495) 465-52-64.
Список литературы
1. Galié N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J. 2009; 30: 2493–2537.
2. Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.
3. Galie N., Palazzini M., Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur. Respir. J. 2010; 36: 986–990.
4. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.
5. Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40: 780–788.
6. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 2008; 31: 891–901.
7. Hara S., Morishita R., Tone Y. et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1995; 216: 862–867.
8. Boxer L.A., Allen J.M., Schmidt M. et al. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J. Lab. Clin. Med. 1980; 95: 672–678.
9. Tuder R.M., Cool C.D., Geraci M.W. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1999; 159: 1925–1932.
10. Christman B.W., McPherson C.D., Newman J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992; 327: 70–75.
11. Olschewski H., Walmrath D., Schermuly R. et al. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Ann. Intern. Med. 1996; 124: 820–824.
12. Krause W., Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur. J. Clin. Pharmacol. 1986; 30: 61–68.
13. Sablotzki A., Hentschel T., Gruenig E. et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur. J. Cardiothorac. Surg. 2002; 22: 746–752.
14. Steudel W., Hurford W.E., Zapol W.M. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999; 91: 1090–1121.
15. Gessler T., Schmehl T., Hoeper M.M. et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 2001; 17: 14–19.
16. Hoeper M.M., Schwarze M., Ehlerding S. et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. 2000; 343: 1866–1870.
17. Ventavis (iloprost). South San Francisco, Calif: Actelion Pharmaceuticals US Inc.; 2006.
18. Schermuly R.T., Schulz A., Ghofrani A. et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther. 2002; 303: 741–745.
19. Olschewski H., Simonneau G., Galie N. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002; 347: 322–329.
20. Van Dyke R.E., Nikander K. Delivery of iloprost inhalation solution with the halolite, prodose, and I-neb adaptive aerosol delivery systems: an in vitro study. Respir. Care 2007; 52: 184–190.
21. Krug S., Sablotzki A., Hammerschmidt S. et al. Inhaled iloprost for the control of pulmonary hypertension. Vascular Health and Risk Management 2009; 5: 465–474.
22. Walmrath D., Olschewski H., Grimminger F., Seeger W. NO and alternative inhalational therapy approaches in pulmonary hypertension. Internist (Berl) 1997; 38: 453–460.
23. Ewert R., Opitz C., Wensel R. et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 2000; 89: 987–999.
24. Olschewski H., Ghofrani H.A., Schmehl T. et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 2000; 132: 435–443.
25. Olschewski H., Ghofrani H.A., Walmrath D. et al. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intens. Care Med. 1998; 24: 631–634.
26. McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–1263.
27. Hoeper M.M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691–694.
28. Opitz C.F., Wensel R., Winkler J. et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. 2005; 26: 1895–1902.
29. D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343–349.
30. Bayer Schering Pharma AG. Open-label, uncontrolled, long-term surveillance study of iloprost aerosol inhalation therapy in the treatment of patients with primary or secondary pulmonary hypertension. Date last updated: May 2007.
31. Olschewski H., Hoeper M.M., Behr J. et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 2010; 104: 731–740.
32. Frost A.E., the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am. J. Respir. Crit. Care Med. 2007; 175 (Suppl.): A1001.
33. Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79: 377–382.
34. Hegewald M.J., Elliott C.G. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009; 135: 536–537.
35. Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.
36. Baughman R.P., Judson M.A., Lower E.E. et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis. Vasc. Diffuse Lung Dis. 2009; 26: 110–120.
Рецензия
Для цитирования:
Авдеев С.Н. Перспективы терапии легочной артериальной гипертензии ингаляционным илопростом. Пульмонология. 2012;(1):95-102. https://doi.org/10.18093/0869-0189-2012-0-1-95-102
For citation:
Avdeev S.N. Future development of therapy with inhaled iloprost in pulmonary arterial hypertension. PULMONOLOGIYA. 2012;(1):95-102. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-1-95-102
Просмотров:
582
Послать статью по эл. почте 